Pavel Farkas

Pavel Farkas graduated and earned a Doctor of Pharmacy degree from J.A.Comenius University and Institute of Experimental Endocrinology of Slovak Academy of Sciences in Bratislava, Slovakia, completed a specialization degree in Clinical Pharmacy as the National Institute of Oncology in Bratislava, Slovakia, and Pharmaceutical Medicine at the Charles University in Prague, Czech Republic. He joined a generic pharmaceutical industry following a career in the field of basic pharmacological and endocrinological research and has been working in the area of clinical development of generic products for over 20 years.

He joined PLIVA in 2004 with responsibilities and experience covering pharmacokinetic, bioequivalence and therapeutic equivalence studies for generic products, conducted mostly for EU/CEE, US and Canadian regulatory submissions as well as respective GCP and regulatory aspects. Pavel Farkas is currently responsible for PLIVA/TEVA’s R&D Biopharmaceutics operations, acting as a member of Bioequivalence Working Group of European Generic Association (EGA) and Steering Committee of AAPS Generic Pharmaceuticals Focus Group.